World Stroke Day: Key Risk Factors Atrial Fibrillation and Hypertension Need Detection and Treatment (y 2)

This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO Co., Ltd. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO Co., Ltd. assume no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.

References

1. Camm A et al. Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. Europace. 2015;17:1007-1017.

2. Banegas JR et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J. 2011;32:2143-52. // Tocci G et al. Blood pressure control in Italy: analysis of clinical data from 2005-2011 surveys on hypertension. J Hypertens. 2012;30:1065-74.

3. Chugh SS et al. Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-847.

4. Institute for Health Metrics and Evaluation. Global Burden of Disease. Available at: http://www.healthmetricsandevaluation.or.... Last accessed September 2015.

5. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982;306:1018-1022.

6. Healey JS et al. Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. Am J Cardiol. 2003;91(10A) :9G-14G.

7. Mancia et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-357.

8. Whelton P et al. National High Blood Pressure Education Program Coordinating Committee. Primary prevention of hypertension: Clinical and public health advisory from the National High Blood Pressure Education Program. JAMA. 2002;288:1882-1888.

9. Mourad, JJ et al. Objective for 2015:70% of treated and controlled hypertensive patients. J Mal Vasc. 2012;37(6):295-9.

10. Volpe M et al. 2012 consensus document of the Italian Society of Hypertension (SIIA): strategies to improve blood pressure control in Italy: from global cardiovascular risk stratification to combination therapy. High Blood Press Cardiovasc Prev. 2013;20(1) :45-52.

11. Rohla M et al. Blutdrucksenkung in der Primärversorgung Wiens. Ärzte Krone. 2015;9:38-40.

12. Camm A et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal. 2010;31:2369-429.

13. Ogilvie IM et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123:638-645e4.

14. European Federation of Pharmaceutical Industries and Associations. Patient Adherence. Available at: http://www.efpia.eu/topics/people-health/patient-adherence. Last accessed October 2015.

15. McAlister FA et al. Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ. 2011;183;1007-13. // Campbell et al. Increases in Antihypertensive Prescriptions and Reductions in Cardiovascular Events in Canada. Hypertension. 2009;53;128-134.

16. WHO. Q&As on Hypertension. Available at: http://www.who.int/features/qa/82/en. Last accessed October 2015.

Contact

Lydia Worms (Europe)

Daiichi Sankyo Europe GmbH

Edoxaban Comm. & Product PR Europe